Dulaglutide vs Icotrokinra
Overview
Dulaglutide is primarily a weight management & metabolic peptide, while Icotrokinra is used for immune support.
This page compares Dulaglutide and Icotrokinra across their primary use, typical dosing, reported benefits and side effects, and U.S. regulatory status. For the full monograph on either compound — mechanism of action, clinical research, and references — follow the article links.
Side-by-side comparison
| Dulaglutide | Icotrokinra | |
|---|---|---|
| Category | Weight Management & Metabolic | Immune Support |
| Regulatory status (US) | FDA approved | FDA approved |
| Typical dosage | 0.75-4.5 mg | — |
| Frequency | weekly | — |
| Reported benefits | Blood sugar control, weight management, cardiovascular benefits | — |
| Reported side effects | Nausea, diarrhea, injection site reactions | — |
Key differences
Primary use. Dulaglutide is categorised under Weight Management & Metabolic, while Icotrokinra falls under Immune Support. Their differing categories mean they are usually chosen for different goals rather than as direct substitutes.
Regulatory status. Dulaglutide: FDA-approved. Icotrokinra: FDA-approved.
Dosing. Dulaglutide is typically dosed at 0.75-4.5 mg (weekly). Typical dosing for Icotrokinra is not catalogued.
Can you stack them?
Some protocols combine peptides, but stacking Dulaglutide and Icotrokinra has not been validated for safety or efficacy in controlled trials. Combining compounds can change their effects and risks. Nothing here is medical advice — consult a qualified healthcare provider before starting or combining any protocol.
Frequently asked questions
- What is the difference between Dulaglutide and Icotrokinra?
- Dulaglutide is primarily a weight management & metabolic peptide, while Icotrokinra is used for immune support. Dulaglutide is FDA-approved for one or more indications, whereas Icotrokinra is FDA-approved for one or more indications.
- What is Dulaglutide used for?
- Weekly GLP-1 (Trulicity).
- What is Icotrokinra used for?
- Oral macrocyclic peptide. First-in-class IL-23 receptor antagonist. FDA approved March 17, 2026 for plaque psoriasis.
- Can you take Dulaglutide and Icotrokinra together?
- Some users combine peptides within a single protocol, but stacking Dulaglutide and Icotrokinra has not been established as safe or effective in controlled trials. Neither this comparison nor PeptideSciences101 is medical advice — consult a qualified healthcare provider before combining any compounds.
- Is Dulaglutide or Icotrokinra FDA-approved?
- Dulaglutide is FDA-approved for one or more indications. Icotrokinra is FDA-approved for one or more indications.
Read the full articles
- Dulaglutide — full monograph: mechanism, research, dosing & references
- Icotrokinra — full monograph: mechanism, research, dosing & references